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ABSTRACT
The effect of omega-3 enhanced fish consumption on C-Reactive Protein levels in
post-menopausal women.
Megan Moran
Heart disease is the leading killer of women in the United States, and the risk is 2-3 times
greater in post-menopausal than pre-menopausal women. C-Reactive protein (CRP) is an
inflammatory marker that has been identified as a risk factor for heart disease. The
objective of this study was to determine if increased consumption of omega-3 fatty acids,
known for their anti-inflammatory properties, reduced CRP levels in post-menopausal
women. A sample of 29 women was recruited to participate in the study. Participants
were randomly assigned to two groups, experimental and control. The women were
instructed to follow a heart healthy diet for eight weeks and to avoid all fish, seafood, and
omega-3 enhanced products for the duration of the study (8 weeks). In addition to the
heart healthy diet and restricted omega-3 guidelines, subjects in the experimental group
were provided two 4 ounce servings of omega-3 enhanced trout each week. The control
group subjects were instructed on the same diet guidelines but were not given the omega3 enhanced trout. Seven day food diaries were recorded and blood tests were performed
to determine CRP, interleukin-6 (IL-6), total cholesterol, HDL cholesterol, LDL
cholesterol, VLDL cholesterol and triglyceride levels at the beginning and end of the
study. No significant pre- to post-study changes between groups were seen for CRP
(p=0.34), total cholesterol (p=0.64), HDL cholesterol (p=0.65), LDL cholesterol
(p=0.50), VLDL cholesterol (p=0.91) and triglycerides (p=0.92). Participants in the fish
group significantly increased their consumption of omega-3 fatty acids (p=0.004) during
the eight week study. A majority (87.5%) of the experimental group and 85.7% of the
control group experienced no change or a decrease in CRP. A similar trend was evident
for Il-6 levels. The addition of two servings of omega-3 enhanced trout per week for eight
weeks was successful in increasing n-3 intake in post-menopausal women; however the
increased n-3 intake did not produce significant changes in markers of inflammation over
the course of the study.
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INTRODUCTION
The leading cause of death in women in the United States is coronary heart disease
(CHD), with rates 2-3 times greater among post-menopausal than pre-menopausal women.1
Additionally, 64% of all women who die suddenly from CHD have had no prior symptoms of the
disease.2 Identifying additional non-traditional risk factors and methods of treatment, including
both medications and lifestyle modifications, is of great interest in reducing rates of CHD.
CHD is a condition where blood vessels leading to the heart narrow, limiting the supply
of blood and oxygen to the heart, putting a person at increased risk for a myocardial infarction
(heart attack).3 Researchers have been investigating the role of inflammation in atherosclerosis,
the process of plaque formation that leads to narrowing of the arteries. C-reactive protein (CRP)
is a marker of inflammation, causing it to gain attention in recent years as a risk factor for CHD. 4
Moreover, CRP has been declared a better predictor of risk for coronary events than traditional
indicators, such as LDL cholesterol.5 This is especially important as LDL cholesterol and CRP
values are not correlated, meaning that individuals may have low to normal LDL cholesterol but
have high CRP values or vice versa. CRP is also relatively stable and inexpensive to measure.6
The lack of correlation between CRP and LDL cholesterol and ease of measuring in a clinical
setting is further justification for including CRP as a screening took for CHD.
Serum CRP values between 1 mg/L and 10 mg/L are of importance in determining CHD
risk.4 Serum CRP levels less than 1 mg/L indicate the patient is at low risk, 1 mg/L to 3 mg/L
indicate intermediate risk and greater than 3 mg/L indicate a high risk. Individuals with CRP
values greater than 10 mg/L should be retested and examined to exclude other health conditions
such as infections, autoimmune diseases, or cancer that may be causing the high values.4
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Scientists are currently interested in determining which lifestyle factors play a role in
reducing CRP levels. Several studies have looked at the effects of dietary components, including
fiber7, arginine8, fruits and vegetables9 and fish10 on levels of CRP due to their cholesterol
lowering and anti-inflammatory properties. Fish and fish oil are of particular interest because of
the omega-3 (n-3) fatty acids they contain. In addition, research has been done to determine the
effect of exercise on levels of CRP.11 This research study will primarily focus on the effects of
fish consumption on CRP levels in post-menopausal women. This document will outline the
study methods, specific aims and results of the project, but first, a review of the literature will
introduce the reader to current understandings of the role of CRP in CHD.

2

REVIEW OF LITERATURE

C-Reactive Protein and Heart Disease
C-reactive protein (CRP) is a protein produced in the liver that is being investigated as a
predictor of future coronary events.12 CRP plays a role in atherosclerosis in several ways - it is
deposited in atherosclerotic plaques, activates macrophages, aids in LDL cholesterol uptake,
increases IL-6 production, and promotes inflammatory responses.4, 13, 14 CRP has been found to
be positively correlated with BMI, triglycerides, fasting glucose, and blood pressure and
negatively correlated with HDL cholesterol levels, all of which are indicators for risk of future
coronary events.15-17
Several studies have found a positive relationship between increased CRP and risk for
future coronary events.12, 15, 18 In a three year study involving 28,263 healthy post-menopausal
women from the Women’s Health Study, high sensitivity CRP (hsCRP) was found to be a strong
predictor of future coronary events (death from CHD, nonfatal MI or stroke, or coronaryrevascularization procedures).12 When comparing baseline levels of several inflammatory
markers including CRP, interleukin-6 (IL-6), serum amyloid A (SAA) and soluble intercellular
adhesion molecule type 1 (sICAM-1), CRP was most strongly associated with risk of coronary
events. In a univariate analysis, a relative risk of 4.4 (95%CI: 2.2 to 8.9, P<0.001) was noted for
women in the highest quartile of CRP versus the lowest quartile. The relative risk for postmenopausal women with “low-risk” values for LDL cholesterol (below 130 mg/dL), but in the
highest quartile of CRP, was 3.1 (95%CI: 1.1 to 8.3, p=0.03).
Similar results were seen in a population of 9,758 men ages 50-59 years old followed for
a period of 5 years in the PRIME study.15 At baseline, all participants were free of heart disease.
CRP was found to be significantly correlated with increased risk for CHD events, specifically
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nonfatal MI and coronary death (p=0.01). The relative risk for patients with CRP values in the
highest tertile versus the lowest tertile was 1.92 (95%CI: 1.14-3.22). Concurring results were
seen by Danesh, et al.18 in the Reykjavik Study regarding the role of CRP in predicting the risk
of CHD. The study population consisted of 2,459 men and women who experienced a nonfatal
MI or death from CHD and 3,969 control subjects. The odds ratio for CHD risk was 1.45
(95%CI: 1.25-1.68) when comparing the baseline CRP values for the highest third of the
population of the study to the lowest third after adjustment for confounding factors. An updated
meta-analysis performed by the researchers concluded an odds ratio of 1.49 (95%CI: 1.37 to
1.62, p=0.01) for patients in the highest tertile versus lowest tertile of baseline CRP values. This
is less than the odds ratio of 2.0 (95%CI: 1.6 to 2.5) that Danesh, et al. reported in a prior metaanalysis.19

Lifestyle Factors
With the emerging evidence that elevated CRP is correlated with an increased risk of
heart disease, researchers are interested in finding lifestyle factors, such as physical activity and
dietary components, that can affect CRP levels. Colbert11 investigated the effect of exercise and
non-exercise (i.e. housework, gardening) physical activity on CRP levels in a population of black
and white men and women between the ages of 70-79 years. The researchers determined that
CRP levels were lower for those reporting higher amounts of physical activity and non-exercise
physical activity after adjustment for confounding factors, such as age, sex, race and diseases
associated with inflammation (p=0.018). The researchers concluded that increased physical
activity, in the form of exercise and non-exercise activity, is associated with lower levels of CRP.
Mora, et al20 aimed to quantify which traditional and non-traditional risk factors were
affected the most by physical activity, thus contributing the most to the reduced risk for
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cardiovascular events associated with increased physical activity. In this study, the researchers
assessed participants for CHD, a form of cardiovascular disease (CVD). CVD also includes
cardiovascular events such as nonfatal myocardial infarction and nonfatal ischemic stroke.
Participants were a subset of 27,055 apparently healthy women from the Women’s Health Study.
Baselines measurements were obtained for traditional risk factors for CVD including lipids,
weight, height and hypertension, and non-traditional risk factors such as CRP, fibrinogen and
soluble intercellular adhesion molecule-1 (sICAM-1). Follow up surveys assessing for
cardiovascular events including CHD and nonfatal MI were completed by participants every 6 or
12 months. It was determined that inflammatory/hemostatic biomarkers, such as hsCRP, have a
significant involvement in the physical activity associated risk reduction for CHD (p=0.01) but
not CVD risk (p=0.1). The researchers concluded that 59% of the reduction in CVD rates and
35.5% of the reduction in CHD rates that is associated with increased physical activity can be
explained by the traditional and non-traditional risk factors investigated in this study. The
inflammatory and hemostatic biomarkers investigated (hsCRP, fibrinogen and sICAM-1) were
found to be the most influential in explaining the reduced risk of CVD and CHD associated with
increased physical activity. The change in inflammatory and hemostatic biomarkers explained
32.6% of the reduction in CVD risk and 20.9% of the reduction in CHD risk seen with increased
physical activity.
Dietary Components
In addition to physical activity, dietary components may influence levels of CRP. Dietary
arginine8, fiber9, cherries21, strawberries22 and omega-3 fatty acids9 have been linked to reduced
levels of CRP. Arginine, a component of nuts and fish, has been investigated due to its reported
antioxidant and anti-inflammatory properties.8 Data from the NHANES III study showed that
participants who consumed the highest amount of arginine, compared to those with median
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consumption, were 30% less likely to have CRP values above 3.0 mg/L. Additionally, those who
consumed the lowest amounts of arginine were more likely to have increased levels of CRP
(P<0.05).
Consumption of fruits and vegetables is another potential dietary factor in decreasing
CRP levels due to the anti-inflammatory properties of their antioxidant components.9 Cherries
are rich in antioxidants, including anthocyanins, which have been shown to reduce
inflammation.21 A study of 10 healthy women between the ages of 22 and 40 years old showed a
decrease in CRP levels 3 hours after consumption of Bing sweet cherries (P<0.1), however no
decrease was noted 5 hours after consumption. Strawberries also have a potential role in
reducing the risk for CVD.22 Strawberries are a rich source of flavonoids, fiber, folate, vitamin C
and potassium, which contribute to their potential heart healthy effects. Sesso, et al. 22 noted no
significant relationship between low strawberry consumption (rarely/never) and CVD risk among
a subset of the participants in the Women’s Health Study. However, a borderline significant
association for reduced CRP values was seen in women with increasing strawberry consumption
(p for trend = 0.012).
Fiber, which is found in fruits and vegetables as well as whole grains, has also been
shown to play a role in reducing CRP levels.7, 9 Twenty eight women and 7 men were randomly
assigned a diet containing 30 g/d of fiber from high fiber foods or a fiber supplement.7
Participants were either lean, non-hypertensive (n=18) or obese hypertensive (n=17) with a mean
age of 38.3 +/- 1.2 years. In lean participants, CRP levels decreased by 30% (P<0.05) and 40%
(P<0.05) in the high-fiber and fiber supplemented groups, respectively. A decrease was seen in
obese patients; however the changes were not significant.
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There have been mixed results presented on the relationship of CRP levels to total fat,
saturated fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids.23, 24 While the
mechanism remains unclear, a strong association has been made between increased intake of n-3
fatty acids and a lower risk of cardiac events.25 One proposed mechanism involves competitive
inhibition between arachadonic acid (ARA), an omega-6 fatty acid, and docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA), two long-chain omega-3 fatty acids. ARA is a
substrate for proinflammatory eicosanoids which play a role in atherogenesis. EPA and DHA can
displace ARA in cell membranes, thus making it unavailable for eicosanoid production.26 The
eicosanoids produced by the n-3 fatty acids are much less reactive than those produced by ARA,
and reduce inflammation, vasoconstriction and platelet aggregation.25 In addition to decreasing
proinflammatory eicosanoid production, EPA and DHA impair production of proinflammatory
cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha.27 While many cytokines
can play a role in hepatic CRP synthesis, IL-6 is the primary mediator.28 DHA and EPA can be
made in the body by the conversion of the omega-3 fatty acid alpha-linolenic acid (ALA),
however this conversion is very inefficient.29 It is estimated that less than 5% of the ALA
consumed is converted to DHA and EPA.

Fish Oil Supplementation
Fatty fish are an excellent source of DHA and EPA. Thus there is an interest in
determining if a relationship between fish oil supplementation or fatty fish consumption and
decreased CRP exists. The effect of fish oil supplements on CRP levels was examined in men
and women between the ages of 50 and 70 years old.30 This study was performed on 43 men and
41 post-menopausal women. Participants were randomly selected within strata of habitual fish
consumption, diastolic blood pressure and sex to receive either a placebo or a fish oil supplement
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pill. The fish oil supplement provided a daily supplement of 3.5 grams of fish oil (1.5 g/day n-3
fatty acids): 700 mg EPA, 560 mg DHA and 260 mg of other n-3 fatty acids. The placebo
contained high-oleic-acid sunflower oil. Participants were asked to avoid fish, seafood or
additional fish oil supplements starting 4 weeks before the study until the end of the 12 week
study. With the exception of the fish restriction, participants were to maintain their normal diet
and lifestyle during the study and to record any illness, medications or changes to their normal
lifestyle habits during the study. Three participants were excluded from this study due to CRP
levels greater than 10 mg/dL and flu like symptoms prior to blood collection. Comparison of
baseline CRP levels to CRP levels after the 12 week study revealed that median changes in CRP
levels were +0.01 mg/dL and -0.17 mg/dL for the fish oil and placebo groups, respectively. The
changes in the two groups were not significantly different (p=0.057). From this, the researchers
determined that supplementation with fish oil did not lower CRP levels in healthy middle-aged
participants.
Similar results were seen in a population of 60 healthy volunteers (25 women, 35 men,
mean age 38 years) given either 6.6g n-3 PUFA/day, 2.0 g n-3 PUFA/day or a placebo of 7 g
olive oil/day.16 The high dose of PUFA contained 3.0 g EPA and 2.9 g DHA. The low PUFA
dose contained 0.9 g EPA, 0.8g DHA. Supplements were taken for 12 weeks with blood samples
obtained at baseline and after 12 weeks of supplementation. No reductions in CRP were seen
after supplementation with fish oil in either group. However the researchers noted that the
subjects in this study were healthy and had low baseline CRP values, so a large reduction in CRP
from baseline was not expected.
More promising results with fish oil supplementation have been seen in male patients
with a history of a myocardial infarction (MI).31 In a study of 40 men in a cardiac rehabilitation
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program after MI, CRP decreased in participants given a daily supplementation of DHA and
EPA over a 12 month period (P<0.05). CRP was significantly decreased in the supplement group
from a baseline value of 3.9 mg/L to 3.12, 2.48 and 2.01 mg/L at months 6, 9 and 12 of the
study, respectively, (P<0.05). Significant differences between the supplement and control groups
were noted at months 6 and 12 (P<0.05). CRP levels showed a significant inverse relationship
with the plasma concentration of EPA+DHA (r = -0.52, p=0.03) and EPA (r = -0.51, p=0.04).
The supplement was given in the form of 500 mL/day skim milk containing 19 g/L total fat, 2.1
g/100g fat of EPA, 1.2 g/100g fat of DHA, 54.4 g/100g fat of oleic acid, and 300 g/L folic acid.
The supplement was also fortified with vitamins A, B-6, D and E. Participants in the control
group received 500 mL/d skim milk fortified with vitamins A and D that contained undetectable
amounts of EPA and DHA and 21.5g/100g fat of oleic acid. Similar results with fish oil
supplementation were also seen in hypertriglyceridemic men.32 Thirty four men between the ages
of 39 and 66 years old with triglyceride values greater than 150 mg/dL were randomly assigned
to a group receiving 3 g DHA/day or a placebo of olive oil for 90 days, following an initial 8 day
period of no supplementation. CRP concentrations were not significantly changed after 45 days,
however a decrease of 15% was noted after 91 days (p<0.05). These results suggest that
supplementation with fish oil decreases CRP concentration, but that sufficient time must be
given before a decrease can be seen.

Fish Consumption
Fish oil supplements are a convenient method for increasing consumption of marine
derived n-3 fatty acids on a daily basis; however study results have been mixed on their ability to
decrease levels of CRP. It is intuitive to question if the results would be different when DHA and
EPA were consumed directly from fatty fish as opposed to a supplement that has undergone
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many processing steps and may not include all of the beneficial nutrients found in the whole
food.
Fish consumption was shown to have a beneficial effect on CHD and total mortality risks
in diabetic women.33 The participants in this study were a subpopulation of nurses participating
in the Nurses’ Health Study. Nurses between the ages of 30 and 55 (in 1976) who had reported
physician diagnosed diabetes between 1976 and 1994 were included in this study. Medical
histories and lifestyle information surveys were collected at baseline and every 2 years thereafter.
Those who had reported any history of heart disease, stroke or cancer on or before the 1980
questionnaire were excluded from this analysis. A semiquantitative food frequency questionnaire
(FFQ) was included with the follow up surveys that allowed the researchers to quantify fish and
long-chain n-3 fatty acid consumption. Fish oil supplementation was not investigated in this
study due to lack of participant use. An increased consumption of fish was found to be
significantly associated with decreased incidence of CHD (adjusted for age; p for trend = 0.003).
Further analysis, determined the relative risk factors to be 0.70, 0.60, 0.65 and 0.38 for fish
consumption 1-3 times per month, once per week, 2-4 times per week and 5 or more times per
week, respectively (p for trend = 0.002). A lower risk of fatal CHD and nonfatal myocardial
infarction was significantly associated with increased fish consumption. A decreased risk for
CHD was also associated with n-3 fatty acid intake, however not as strongly as with fish
consumption. This discrepancy may have been due to errors in estimating the n-3 fatty acid
content of fish or other components of the diet.
In the ATTICA study, researchers looked at the relationship of fish consumption on
inflammatory markers, such as CRP, in individuals with no prior evidence of cardiovascular
disease.10 In this study of 1,514 men and 1,528 women, participants completed a food frequency
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questionnaire reporting their weekly consumption of a variety of foods over the course of the
prior year. Fish consumption was ranked on a scale from none (<150 g/week) to frequent (>300
g/week). Blood samples of participants after a 12 hour fast were analyzed for inflammatory
markers (CRP, IL-6, serum amyloid A, TNF-alpha and white blood cell counts). Information was
collected to categorize participants based on age, gender, average annual income, years of
schooling, leisure time physical activity and smoking status. BMI, blood pressure and serum
cholesterol levels were determined. All inflammatory markers examined were inversely related
to fish consumption and to n-3 intake. Those in the highest fish consumption category had lower
levels of inflammatory markers than those who were moderate or rare consumers of fish (r=0.12, p<0.001). An inverse relationship between all inflammatory markers and fish consumption
was still noted after adjusting for potential confounding factors. In addition, the researchers in
the ATTICA study noted that a strong inverse relationship between fish/n-3 consumption and
inflammatory markers was seen in individuals with diabetes and hypertension, but not those with
hypercholesterolemia. Lastly, the researchers determined that the optimal intake of n-3 fatty
acids was 0.6 g per day to maximize benefits.
Several studies have looked at the effect of fish consumption on CRP levels in Japanese
men and women, since their intake of marine products is higher than in a typical Western diet. 23,
24, 34

Female Japanese dietetic students between the ages of 18 and 22 (n=443) showed an inverse

relationship between CRP and total n-3 fatty acid intake.24 Dietary intake in this population was
obtained using a diet history questionnaire (recall) for the month prior to the study and blood
samples were taken after completion of the diet history. The results showed an inverse
relationship between total n-3 PUFA consumption and CRP levels; however there was not a
significant association between EPA+DHA intake and CRP levels (p=0.62). Odds ratios for
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elevated CRP levels of 0.33 and 1.0 were determined for women consuming n-3 PUFAs in
quantities above and below the median, respectively (95%CI 0.13-0.82, p=0.02).
Similar results were seen in a middle aged population of Japanese men (n = 1556) and
women (n=1461).23 In this study a diet history questionnaire was used to obtain dietary intake for
the month prior to the study. Serum CRP was measured and values were compared to dietary
intakes of the n-3 fatty acids EPA, DHA and alpha-linolenic acid; the n-6 fatty acid linoleic acid;
the n-9 fatty acid oleic acid; and saturated fatty acids palmitic and stearic. There were no
significant associations between increased EPA or DHA intakes and CRP values in men or
women. There was a significant inverse relationship between an increased consumption of total
n-3 PUFAs and CRP level in women (P for trend = 0.02) and a non-significant but similar trend
seen in men (P for trend = 0.409). In participants consuming quantities of EPA+DHA in the
middle tertile of the population, oleic acid and lineoleic acid in men, and oleic acid, lineoleic
acid and ALA in women were inversely related to serum CRP concentrations. This result
suggests that a moderate intake of EPA+DHA may influence the relationship between other fatty
acids and CRP levels.
Investigating the role of fish consumption on CRP levels in an elderly Japanese
population (greater than 70 years old) also showed promising results.34 In this study of 401 men
and 570 women with baseline CRP values below 10 mg/L, dietary intake was collected using a
brief diet history questionnaire for the period of 1 year prior to the study. Low CRP was defined
as values below 1.0 mg/L and high as values above or equal to 1.0 mg/L. Total n-3 PUFA intake
and EPA+DHA intake were related to decreased CRP concentrations; however this was not
statistically significant (p for trend = 0.051 and 0.20, respectively). The risk for high CRP
concentrations significantly decreased with increased consumption of total n-3 PUFAs (Odds
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Ratios (OR) for increasing quartiles: 1.0, 0.72, 0.57, 0.44, P for trend = 0.01) and EPA+DHA
(ORs for increasing quartiles: 1.0, 0.91, 0.76 and 0.54, P for trend = 0.03). Decreasing CRP
concentrations were also seen with increasing EPA consumption and DHA consumption (p for
trend = 0.02 and 0.01, respectively). These results suggest that an increased consumption of n-3
fatty acids, through marine sources such as fatty fish, is associated with a decreased level of
CRP.
In the only known clinical trial published to date regarding fish consumption and CRP
levels, Tsitouras, et al35 investigated the effects of fatty fish and fish oil consumption in twelve
relatively healthy men and women 60-75 years old. Participants consumed a control diet for 6
weeks containing four 6-ounce servings of non-fatty fish per week, no servings of fatty fish, a
corn/olive oil placebo, and limited amounts of trans-fatty acids. After the control period,
participants consumed a similar diet however the non-fatty fish was replaced with fatty fish and a
daily fish oil supplement (15 mL/day, providing 4-5 grams of n-3 fatty acids) was provided for
the duration of 8 weeks. Blood measurements were obtained at baseline, week 6 and week 14 of
the study. There was a significant decrease in the n-6 to n-3 ratio present in red blood cell
membranes after the 8 week intervention diet (p<0.0001). CRP was also significantly decreased
from 0.203 mg/L to 0.073 mg/L in participants after the 8 week period of fatty fish and fish oil
consumption (p<0.008). These data provide evidence that an 8 week intervention period is
sufficient to experience a change in the composition of red blood cell membranes and that an
increased consumption of n-3 fatty acids from fish and fish oil reduces levels of CRP. However,
because the high n-3 diet contained both fish and fish oil supplements, it is impossible to
determine which had a more significant, if any, contribution to the reduced CRP levels. Further
studies are needed to determine if fish consumption alone has the ability to reduce CRP levels.
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While epidemiological studies have shown mixed results regarding the relationship
between increased consumption of fish oil and n-3 fatty acids and CRP levels, promising results
have been seen with fatty fish consumption. This beneficial relationship could be a result of
consuming the n-3 fatty acids from a whole food as opposed to a supplement or because of other
components present in fish, but not in fish oil supplements. To date, there has been one clinical
trial published investigating the role of fatty fish consumption with additional fish oil
supplementation on CRP levels; there are no known studies investigating the role of fatty fish
consumption on CRP levels. With the potential for reduced CRP levels to decrease the risk for
CHD, there is a need for additional intervention studies to determine if a causal relationship
exists between fish consumption and CRP levels.
In West Virginia, fish and n-3 consumption are very low and CHD rates are very high.2
Increasing fatty fish consumption could potentially play a major role in reducing the incidence of
CHD in this population. The availability of n-3 enhanced trout from the WVU Aquaculture
program has provided the opportunity to determine if a causal relationship exists between fish
consumption and CRP levels in post-menopausal women, a group at high risk for CHD, living in
West Virginia. The results from this study will add to the current understanding of dietary roles
as a preventative measure for CHD in post-menopausal women.
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STUDY OBJECTIVES
It has been suggested that a diet high in omega-3 fatty acids will have a beneficial effect
on markers of cardiovascular risk in post-menopausal women. Fatty fish are a rich source of
omega-3 fatty acids. Based on a review of the current literature we generated the following
hypothesis: the risk of coronary heart disease (CHD) in post-menopausal women, as measured by
C-reactive protein (CRP), will be reduced by consuming two servings per week of omega-3
enriched fish when compared to a control group consuming an unmodified diet. We tested this
hypothesis with 3 specific aims by comparing a group of post-menopausal women who
consumed two servings of omega-3 enriched fish to a control group consuming no-fish and
limited omega-3 products.
1. To determine the mean change in serum high sensitivity C-reactive protein (hsCRP) and
compare the mean change between the two groups.
2. To determine the effect of other dietary and lifestyle factors on CRP levels.
3. To compare the mean change in traditional markers of cardiovascular disease risk
including: total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol and
triglycerides between the two groups.
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MATERIALS AND METHODS
Subjects
The Institutional Review Board at West Virginia University (WVU) approved this
research study. Participants were recruited from the WVU and Morgantown, WV communities
using on campus fliers and word of mouth. Additionally, electronic announcements were posted
in the WVU faculty E-News messaging system, and intranets at Ruby Memorial and Monongalia
General Hospitals. The flier distributed on campus and adapted for electronic format can be seen
in Appendix 1. Interested participants were screened for the following criteria:
Inclusionary: Post-menopausal (no menses within the prior 12 months or surgical menopause.
Exclusionary: severe obesity (BMI>40); personal history of coronary heart disease
(myocardial infarction, congestive heart failure, angina, stroke); recent major infection or
injury; chronic inflammatory disease (rheumatoid arthritis, cirrhosis, pulmonary/cystic
fibrosis, glomerulosclerosis, chronic pancreatitis, inflammatory bowel disease, ulcerative
colitis or psoriasis); current cancer; current anti-inflammatory medication; daily aspirin or
ibuprofen usage; hormone replacement therapy (HRT); current tamoxifen usage; current
fish oil or omega-3 supplement usage; current alcohol consumption greater than 1 serving
per day; current smoker; current fatty fish consumption of 1 serving per week or greater;
current consumption of omega-3 enhanced food products.
Participants who were previously on HRT, but had not taken within the 3 months prior to the
start of the study were not excluded. Participants who were willing to stop all of the following
for the duration of the study were also not excluded: daily anti-inflammatory, aspirin and/or
ibuprofen usage; current fish oil or omega-3 supplement usage; current fatty fish consumption of
1 serving per week or greater; current consumption of omega-3 enhanced food products.
Exclusionary criteria were selected to exclude participants diagnosed with cardiovascular disease
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or inflammatory diseases and to decrease factors that would interfere with inflammatory
processes in the body. After screening, participants were randomly assigned to the experimental
(fish) group or the control (no-fish) group by a computer generated randomization.
Study participants were required to attend a pre-study meeting in which study procedures
were explained and subjects provided informed consent and waivers of privacy rights regarding
protected health information (HIPAA). Study instructions were delivered in verbal and written
form. After reviewing study instructions, participants were given the opportunity to ask questions
or withdraw from the study. Participants were given a study folder that included study
instructions, a calendar detailing expectations for the duration of the study, recommendations for
a heart healthy diet, handouts for estimating portion sizes, food diary forms, blood work forms
and copies of all documents signed. Members of the experimental group also received a blank
calendar to record when servings of fish were eaten and recipes for preparing the fish.
Participants also completed a baseline survey and the International Physical Activity
Questionnaire (IPAQ) short form.36 At the completion of the study, participants were required to
attend a post-study meeting where they completed an end of study survey and received copies of
their food diary analysis, bloodwork tests and a form explaining how to interpret these results.
These documents can be seen in Appendix 2.
Sample size calculations estimated that 51 participants were needed to obtain a
significance level of 0.05 and power of 80% for a 0.5 mg/L difference in CRP levels. To account
for a potential 20% attrition rate, a minimum of 60 participants were to be recruited. Forty
women were screened and consented between June 2008 and April 2009. Four of the subjects
withdrew before the study started, six dropped out during the study and one completed all but the
pre- and post-study food logs. A total of 29 women completed the study, 15 in the experimental
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(fish) group and 14 in the control (no-fish) group fish (n=15) and no-fish (n=14) groups.
Bloodwork data are presented for 30 participants due to one experimental group participant
completing both blood tests, but no food diaries (fish group, n=16).
Diet Instructions
At the initial screening, participants were instructed to refrain from consuming fish, any
seafood, omega-3 enhanced/rich foods and daily anti-inflammatory medications through the
duration of the study. At the pre-study meeting, participants were given additional dietary advice.
They were asked to eliminate the above items as well as follow a heart healthy diet that is low in
fat and rich in fruits and vegetables for the duration of the study. Appendix 2 contains the
handout provided to participants listing heart healthy foods. Participants in the experimental
group were to include two servings of the fish provided by the study each week for 8 weeks
(study weeks 2-9). All participants were required to complete a seven day food diary during
weeks 1 and 9 of the study. The diary could be hand written on the blank food diary form
distributed during the pre-study meeting or completed on an electronic version that was available
by request. Table 1 outlines the 12 week schedule the experimental group participants were
provided. The schedule for the control group was identical with the exception of the instructions
for week 2-8. During this time they were instructed to follow a heart healthy diet without any
fish, seafood or omega-3 enhanced products. To increase compliance with the study protocol,
weekly emails were sent to participants that included heart healthy tips and a reminder of the
study requirements for the following week.
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Table 1: 12 week schedule for fish group participants.

Week

0

1
2
3
4
5
6
7
8
9
10
11

Task
Beginning of study meeting: participants received packets containing:
- Instructions for study
- Heart healthy tips
- LabCorp and food diary forms
- Study intake and exercise questionnaires
Participants complete informed consent and HIPPA forms.
All participants have baseline blood test at LabCorp and complete 7 day food diary.
Participants return food diary.
Fish group members receive fish; consume 2 servings.
Fish group members consume 2 servings of fish.
Fish group members consume 2 servings of fish.
Fish group members consume 2 servings of fish.
Fish group members consume 2 servings of fish.
Fish group members consume 2 servings of fish.
Fish group members consume 2 servings of fish.
Fish group members consume 2 servings of fish.
All participants complete and return 7 day food diary.
All participants have end of study blood test at LabCorp.
End of study meeting where:
- Participants complete an evaluation of the study
- Participants receive results from food intake analysis and blood tests

Fish
The fish used in the study were omega-3 enhanced brook trout raised by Dr. Ken
Semmens of the WVU Extension Service and Dr. Jacek Jaczynski from the Department of
Animal and Nutritional Sciences. The fish were raised on a diet enriched with omega-3 fatty
acids (42% by weight of diet). The omega-3 content of the fish was analyzed by Dr. Jaczynski’s
lab. The fish were requested to be cut into approximately 4oz fillets, vacuum sealed and flash
frozen. The mean weight of a sample of 21 fillets was 4.67 ounces (SD=0.55). Participants
received the vacuum sealed fillets with safe handling instructions and suggestions for
preparation. (Appendix 2) Participants had the option of receiving all 16 fillets at one time or
arranging to pick up smaller amounts of fillets throughout the study. The fatty acid composition
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of the brook trout consuming a flax enhanced diet compared to a control diet can be seen in
Table 2.37
Table 2: Fatty Acid Composition of Brook Trout

%FA in total Fatty Acids
Treatment
Control
Flax

Total Fat in a Fillet
4.50%
4.30%

Total Omega 3 FA
26.31
32.8

Other DHA EPA ALA
3.9 14.45 5.17 2.79
4.3 11.09 3.83 13.58

Data Collection and Analysis
Blood samples were drawn and analyzed by LabCorp facilities. CRP and IL-6 levels were
assessed using an immunochemiluminometric assay (ICMA). Total cholesterol, HDL cholesterol
and triglycerides were measured using an enzymatic test. LDL and VLDL levels were calculated
based on the results of the other lipid measurements.
Diet records were analyzed using the Nutrition Data System (NDS) from the University
of Minnesota. Three week days and one weekend day were randomly selected from all seven day
food diaries submitted. Phone verification of the data entered into the NDS system was
completed by asking participants about any food items that were unclear on their food diary.
Total omega-3 consumption for the experimental group was calculated using nutrient
values from NDS and data presented by Dr. Ken Semmens (Table 2). The additional quantity of
omega-3 fatty acids present in the enhanced fish compared to brook trout in the NDS system was
determined. The additional quantity of omega-3 fatty acids consumed from two fish fillets was
averaged over 7 days to compute a daily additional omega-3 consumption amount. This value
was then added to the average daily value of omega-3 consumed as determined in NDS from the
end of study food diary for the experimental group.
Demographic and physical activity data were obtained from self-administered surveys
during the pre-study meeting. An exit survey was administered at the post-study meeting to
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determine participant satisfaction and any major health-related events (weight loss, cardiac
event) that may have occurred during the study. The short International Physical Activity
Questionnaire (IPAQ) was used to obtain physical activity data.36 Participants in the
experimental group recorded the days and meals in which the fish was consumed using a “fish
calendar” provided at the pre-study meeting.

Statistical Analysis
Descriptive statistics were computed for demographic and lifestyle characteristics.
Change in biometric measures and intake were calculated by subtracting the pre-study from the
post-study value for each item. IL-6 was reported as numerical values above 2 or “less than 2”,
making it difficult to quantify change in IL-6 values. To determine change in risk for CVD
associated with change in IL-6, it was assumed that values less than 2 were low risk and values
above 2 were high risk.38 A t-test was then used to compare mean change in total cholesterol,
HDL, LDL, VLDL, triglycerides, CRP and IL-6, as well as mean change in intake of total fat,
saturated fat, trans fat, total omega-3 fatty acids, omega-6 fatty acids in the form of linoleic acid
and fiber by group. Biometric measures and dietary components were compared within group
pre- and post-study using a paired t-test. Finally, chi squared tests were performed to compare
the proportion of participants in the experimental and control groups who experienced an
increase to those who experienced a decrease or no change for total cholesterol, HDL, LDL,
VLDL and triglycerides. A similar test was run to compare the proportion of participants in each
group that experienced an increase to those who experienced a decrease or no change in CVD
risk as defined by levels of CRP and IL-6. All statistical analysis were performed using Stata for
Windows, Version 10.1.

21

RESULTS
Demographic and lifestyle characteristics and for the study population are presented in
Tables 3 and 4. These data represent the 37 women who completed the pre-study survey
including the six women who dropped out prior to completion of the study and the single
participant who completed a majority of the study but did not complete either food diary. Of the
14 women enrolled in the no-fish group, one was single, 11 were married and two were
widowed. In the fish group, two were single, eight married, one widowed and four divorced.
Among the participants who did not complete the study, one was single, five were married and
was one divorced. There were no significant differences in marital status between any of the
groups (p=0.35). All participants had received a high school diploma, GED or higher. All
participants in the no-fish group, all participants that dropped out and all but one in the fish
group reported their race/ethnicity as white, non-Hispanics. One member of the fish group
reported her race/ethnicity as African American, non-Hispanic. There were no significant
differences between education level or race/ethnicity between any of the groups (p=1 and
p=0.54, respectively). There were no significant differences in mean age or body mass index
(BMI) between groups (p=0.43 and p=0.50, respectively).
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Table 3: Demographic Characteristics
No-Fish
n=14
n(%)

Fish
n=16
n(%)

Drop Out
n=7
n(%)

1 (7.14)
11 (78.6)
2 (14.3)
0

2 (13.3)
8 (53.3)
1 (6.7)
4 (26.7)

1 (14.3)
5 (71.4)
1 (14.3)
0

0
3 (21.4)
1 (7.1)
4 (28.6)
6 (42.9)

0
0
2 (13.3)
6 (40.0)
9 (46.7)

0
1 (14.3)
1 (14.3)
3 (42.9)
2 (28.6)

14 (100)

14 (93.3)

7 (100.0)

0

1 (6.7)

0

Mean (SD)
57.7 (6.9)
26.7 (4.8)

Mean (SD)
59.3 (8.4)
27.7 (5.3)

Mean (SD)
55.0 (6.6)
29.5 (5.8)

1

p

Marital Status

0.35
Single
Married
Widowed
Divorced

Education
Grade school or less
High school or GED
Some College
College
Graduate Degree
Race
White (non-Hispanic)
African American (nonHispanic)

Age (years)
2
BMI (kg/m )
1

1.00

0.54

2

p

0.43
0.50

chi squared test; 2ANOVA; significance at p<0.05

Ten participants reported a history of smoking, three in the no-fish group, three in the fish
group and four among the participants that dropped out. There were no significant differences in
smoking history between groups (p=0.25). Exercise frequency reported by the no-fish group on
the pre-study questionnaire was 28.6% a few times a week, 50% once a week and 21.5% less
than once a week. In the fish group, 37.5% exercised a few times a week 50% once a week and
12.5% less than once a week. All participants that dropped out of the study reported exercising
once a week. There were no significant differences between groups in exercise frequency
(p=0.52) or in energy intensity as measured by the IPAQ-short form (p=0.52). A majority of the
population of both groups consumed alcohol a few times a month or less.
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Table 4: Lifestyle Characteristics

No-Fish
Fish
n(%)
n(%)
Smoking History
n=14
n=16
Used to smoke, quit
3 (21.4)
3 (18.8)
Never smoked
11 (78.6)
13 (81.2)
Exercise Frequency
n=14
n=15
A few times a week
4 (28.6)
6 (37.5)
Once a week
7 (50.0)
8 (50.0)
Less than once a week
3 (21.4)
2 (12.5)
Alcohol Frequency
n=14
n=15
Every day
1 (7.1)
2 (13.3)
A few times a week
1 (7.1)
1 (6.7)
A few times a month
3 (21.4)
2 (13.3)
A few times a year
3 (21.4)
7 (46.7)
I never drink alcohol
6 (42.9)
3 (20.0)
Mean (SD) Mean (SD)
n=14
n=16
Exercise Intensity (MET2511.1
1605.6
min/week)
(2751.1)
(1683.9)
1
chi squared test; 2ANOVA; significance at p<0.05

Drop Out
n(%)
n=7
4 (57.1)
3 (42.8)
n=4
0
3 (100.0)
0
n=8
1 (12.5)
1 (12.5)
3 (37.5)
2 (25.0
1 (12.5)
Drop out
n=3
1816.2
(626.4)

p1
0.25

0.52

0.68

p2
0.52

Food diary analysis indicated that participants in the no-fish group did not significantly
vary their diet over the course of the study. As can be seen in Table 5, the no-fish group had
similar intake of total fat (p=0.96), total omega-3 (p=0.14), omega-6 in the form of linoleic acid
(p=0.37), saturated fat (p=0.79) and trans fat (p=0.52) between the initial and final food diaries.
There was a slight decrease in fiber intake from pre- to post-study in the no-fish group, however
this comparison was not significant (p=0.07). In the fish group there were significant differences
in mean total omega-3 and mean fiber consumption pre- and post-study. Mean omega-3
consumption increased from 1.2 to 1.9 grams/day (p=0.004). Mean fiber intake increased from
22.8 grams/day to 24.5 grams/day (p=0.04). No significant differences were evident in the mean
intake of total fat, omega-6, saturated fat or trans fat. The mean differences in fat intake pre- to
post-study between the two study groups were not significant; total fat (p=0.34), total omega-3
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(p=0.11), omega-6 (p=0.95), saturated fat (p=0.24) or trans fat (p=0.11). (Table 6) However,
fiber intake decreased in the no-fish group and increased in the fish group (p=0.007).

Table 5: Pre- and Post-Study Mean Intakes for Fat and Fiber, Within Group Comparisons

No-Fish (n=14)
Pre-Study
Post-Study
Mean (SE) Mean (SE)
Total Fat (g/day)
55.2 (5.5)
55.6 (9.9)
Total Omega-3 (g/day)
1.1 (0.1)
1.4 (0.2)
Omega-6(g/day Linoleic Acid
9.7 (1.0)
11.5 (2.1)
Saturated Fat (g/day)
19.3 (2.5)
18.5 (3.6)
Trans Fat (g/day)
2.8 (0.5)
2.4 (0.7)
Fiber (g/day)
21.4 (1.6)
18.9 (1.8)
Significance at p<0.05; paired t-test.

p
0.96
0.14
0.37
0.79
0.52
0.07

Fish (n=15)
Pre-Study
Post-Study
Mean (SE) Mean (SE)
55.9 (5.1)
65.4 (6.0)
1.2 (0.6)
1.9 (0.2)
10.8 (1.3)
12.4 (1.5)
19.2 (2.2)
22.4 (2.0)
2.3 (0.3)
3.1 (0.5)
22.8 (1.9)
24.5 (2.0)

p
0.11
0.004
0.3
0.09
0.08
0.04

Table 6: Mean Change in Fat and Fiber Intakes Pre- and Post-Study, between Group Comparisons

No-Fish
Fish
n=14
n=15
Mean (SE) Mean (SE)
p
Total Fat (g/day)
0.4 (7.7)
9.5 (5.6)
0.34
Total Omega-3 (g/day)
0.3 (0.2)
0.7 (0.2)
0.11
Omega-6 (g/day Linoleic Acid)
1.8 (1.9)
1.6 (1.5)
0.95
Saturated Fat (g/day)
-0.8 (2.9)
3.2 (1.7)
0.24
Trans Fat (g/day)
-0.4 (0.6)
0.8 (0.4)
0.11
Fiber (g/day)
-2.5 (1.3)
1.7 (0.7)
0.007
Mean change calculated as post-study value minus pre-study value. Significance at p<0.05; ttest.

Table 7 presents baseline and post study biochemical measurements by group. Pre- and
post-study data include the 29 participants that completed the study and the one participant that
completed all but the food diaries. There were no significant differences in baseline total CHL,
HDL, LDL, VLDL, triglycerides or CRP values between the no-fish and fish groups. Similar
results were seen for the post-study measurements. There were no significant differences in the
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mean change of the biochemical measurements between the fish and no-fish groups or within
groups. (Tables 8 and 9)

Table 7: Pre- and Post-Study Mean Lipid Levels and CRP, Between Group Comparisons

No-Fish
n=14
Mean (SE)
198.8 (8.7)
Total CHL (mg/dL)
67.4 (5.0)
HDL (mg/dL)
107.3 (8.0)
LDL (mg/dL)
24.1 (4.4)
VLDL (mg/dL)
Triglycerides (mg/dL) 120.4 (22.2)
1.5 (0.4)
CRP (mg/L)
Significance at p<0.05; t-test.

Fish
n=16
Mean (SE)
188 (7.5)
66.8 (3.6)
101.5 (7.0)
19.8 (2.2)
98.5 (11.0)
3.9 (1.6)

p
0.36
0.91
0.59
0.37
0.37
0.17

No-Fish
n=14
Mean (SE)
200.1 (8.0)
67.0 (4.3)
109.6 (8.0)
23.5 (3.6)
117.8 (18.2)
1.8 (0.4)

Fish
n=16
Mean (SE)
193 (7.0)
65.4 (3.5)
108.1 (7.6)
19.5 (1.8)
97.5 (9.0)
2.5 (0.6)

p
0.51
0.77
0.90
0.31
0.31
0.34

Table 8: Mean Change in Lipid Levels, Pre- and Post-Study, Between Group Comparisons

No-Fish
Fish
n=14
n=16
Mean (SE) Mean (SE)
p
Total CHL (mg/dL)
1.3 (4.5)
5 (6.1)
0.6
HDL (mg/dL)
-0.4 (1.6)
-1.4 (1.3)
0.7
LDL (mg/dL)
2.3 (4.2)
6.6 (4.6)
0.5
VLDL (mg/dL)
-0.6 (1.8)
-0.3 (2.2)
0.9
Triglycerides (mg/dL)
-2.6 (9.3)
-1 (11.0)
0.9
CRP (mg/L)
0.3 (0.2)
-1.4 (1.6)
0.3
Mean change calculated as post-study value minus pre-study value. Significance at p<0.05; ttest.
Table 9: Pre- and Post-Study Mean Lipid Levels and CRP, Within Group Comparisons

No-Fish (n=14)
Pre-Study
Post-Study
Mean (SE)
Mean (SE)
198.8 (8.7)
200.1 (8.0)
Total CHL (mg/dL)
67.4 (5.0)
67 (4.3)
HDL (mg/dL)
107.3 (7.9)
109.6 (8.0)
LDL (mg/dL)
24.1 (4.4)
23.5 (3.6)
VLDL (mg/dL)
120.4 (22.2) 117.8 (18.2)
Triglycerides (mg/dL)
1.5 (0.4)
1.8 (0.4)
CRP (mg/L)
Significance at p<0.05; paired t-test.

p
0.8
0.8
0.6
0.8
0.8
0.2

Fish (n=16)
Pre-Study
Post-Study
Mean (SE) Mean (SE)
188 (7.5)
193 (7.0)
66.8 (3.6)
65.4 (3.5)
101.5 (7.0) 108.1 (7.6)
19.8 (2.2)
19.5 (1.8)
98.5 (11.0)
97.5 (9.0)
3.9 (1.6)
2.5 (0.6)

p
0.4
0.3
0.2
0.9
0.9
0.4
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There were no significant differences in the proportion of participants with increased lipid levels,
CRP risk levels and IL-6 risk levels between the two groups. (Table 10)

Table 10: Proportion of Participants with Increased Lipid, CRP, and IL-6 Levels, Between Group
Comparisons

No-Fish
n=14
n(%)
Decrease or
No Change Increase
Total CHL (mg/dL)
7 (50.0)
7 (50.0)
HDL (mg/dL)
8 (57.1)
6 (42.9)
LDL (mg/dL)
6 (42.9)
8 (57.1)
VLDL (mg/dL)
7 (50.0)
7 (50.0)
Triglycerides (mg/dL)
6 (42.9)
8 (57.1)
CRP Risk Level
12 (85.7)
2 (14.3)
IL-6 Risk Level
11 (78.6)
3 (21.4)
Significance at p<0.05; Chi squared test.

Fish
n=16
n(%)
Decrease or
No Change
6 (37.5)
10 (62.5)
5 (31.3)
7 (43.8)
7 (43.8)
14 (87.5)
11 (73.3)

Increase
10 (62.5)
6 (37.5)
11 (68.8)
9 (56.3)
9 (56.3)
2 (12.5)
4 (26.7)

p
0.49
0.77
0.51
0.73
0.96
0.89
0.74
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DISCUSSION
The results of this study show that incorporating two servings of an omega-3 enhanced
trout per week for 8 weeks into the diet of post-menopausal women was successful in increasing
n-3 consumption; however no changes in markers of inflammation were seen as a result of the
increased n-3 consumption.
Participants in both study groups were asked to follow a heart healthy diet omitting any
foods high in omega-3 fatty acids, such as flax seeds, fish, seafood and omega-3 enhanced
products for the duration of the study. Participants in the fish group significantly increased their
average daily consumption of omega-3 fatty acids by 0.7 g/day (SEM=0.2), which was expected
from the increased consumption of fish. An unexpected increase in omega-3 consumption was
evident in the no-fish group (mean change=0.3 g/day SEM=0.2), however the mean daily intake
from end of study diet records was not significantly greater that the intake from the baseline diet
records. This apparent increase in omega-3 intake in the control group likely reflects normal
variation in the diets of individuals. When the mean change in intake was compared between the
two groups the difference was not significant. Post-study mean omega-3 intake for the fish group
was 1.9 g/day (SEM=0.2) and for the no-fish group was 1.4 g/day (SEM=0.2), both of which are
greater than the 0.6 g/day recommended by Zampelas et al to maximize benefits.10 The amount
of omega-3 consumed in this study is less than that reported in other studies. Tsitouras35
supplemented with 4-5 g/day of fish oil in addition to four 6-ounce servings of fish/week (n-3
content of fish not reported).
Elevated levels of the inflammatory marker CRP are associated with an increased risk of
heart disease.4 The American Heart Association recommends consuming 2 servings of fatty fish
per week to reduce the risk of CVD.39 Fatty fish are a rich source of the anti-inflammatory
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omega-3 fatty acids, the components in fish believed to produce the heart healthy benefits. In the
present study, a non-significant decrease in CRP was seen in participants consuming two
servings of an omega-3 enhanced fish per week. The lack of significance could be due to the
small sample size of the study or the amount of omega-3 fatty acids added to the diet in the form
of fish was not sufficient to produce a significant change in CRP levels. Additionally, it is
possible that the decrease in CRP levels, although not statistically significant, may be clinically
significant. Individuals with CRP levels above 3 mg/L are considered at high risk for CVD, 1.03.0 mg/L are at medium risk and below 1.0 mg/L at low risk. The mean CRP levels changed
from a high risk classification of 3.77 mg/L to a medium risk classification of 2.54 mg/L in the
fish group. Tsitouras35 saw a significant, but smaller, change in CRP values than in the present
study (-0.127 mg/L versus -1.23 mg/L), however baseline CRP values were much higher in the
present study (3.77 mg/L versus 0.2 mg/L). Participants in the Tsitouras study consumed 24
ounces of fish per week plus daily fish oil in comparison with 8 ounces of fish per week with no
fish oil supplementation in the present study. Similar results may have been seen if participants
in the current study had been provided with greater than 8 ounces of fish per week.
Based on the change in CRP levels over the course of the study, the majority of
participants in the experimental group (87.5%) experienced no change or a decrease in predicted
CVD risk, only two experimental group participants experienced an increase in CVD risk based
on CRP levels. While the proportion of subjects with decreased or no change in risk was not
significantly different between the two groups, these results are supportive of an inverse
association between omega-3 intake and CRP based CVD risk. Fiber consumption is a potential
modifier of CRP levels. In this study, participants in the fish group significantly increased their
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fiber consumption compared to the no-fish group. This increased fiber consumption may have
played a role in the decreased values of CRP in the fish group.
Elevated blood lipid levels including total cholesterol, LDL cholesterol, VLDL
cholesterol and triglycerides and decreased HDL cholesterol levels are associated with increased
CVD risk. Increased consumption of omega-3 fatty acids has been associated with decreases in
blood triglyceride levels and increases in LDL and HDL cholesterols.39 It has been reported that
4g/day intake of fish oil can result in a 25-30% decrease in triglyceride level, a 5-10% increase in
LDL and a 1-3% increase in HDL. In this study an approximately 4% decrease in triglycerides,
approximately 3% increase in LDL and approximately 2% decrease in HDL were seen in the
experimental group participants. Within group and between group comparisons of blood lipid
measures pre- and post-study were not significantly different. A majority of participants in both
groups experienced no change in risk or decreased risk based on IL-6 levels.
There are several potential reasons why significant results may not have been seen in this
study.

In addition to those already mentioned (small sample size, need for more than 2

servings/week of fish), the composition of the fish fillets may explain the lack of significant
results. As seen in Table 2, the composition of n-3 enhanced fish compared to control fish was
greater in ALA than DHA and EPA. In fact, the presence of DHA and EPA decreased in fish
consuming the flax oil diet. DHA and EPA are the omega-3 fatty acids associated with reduced
risk for CHD. ALA can be converted to DHA and EPA in the body; however this conversion is
very inefficient.29 Providing participants with control fish may have resulted in more promising
results. Another potential reason a significant decrease in CRP was not seen in our study may be
related to the demographics of the study population. Participants were relatively healthy
individuals that did not smoke, drink, have heart disease and were not obese. Repeating the study
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with participants who would be considered unhealthy and have additional risk factors for heart
disease (smoking, obesity, high cholesterol, do not exercise), may prove differing results. Lastly,
participants in the fish group had a non-significant increase in total fat, saturated fat and trans fat
consumption (p=0.11, 0.09 and 0.08 respectively). This increase could be due to participants
preparing their fish in butter and would have an influence on several biomarkers measured in this
study. A replica of this study providing smoked fish would decrease the variation in preparation
methods and would eliminate the need to prepare the fish consuming butter.
There are some weaknesses in this study. First, the small sample size limited the
statistical power of the analysis. Second, self reported food diaries are often a source of error.
There could be inaccuracies in the serving sizes or brands reported. There is also potential for
error in entering missing foods into the NDS program, however this error was minimized by
having a second person verify the data that was entered. Calculating the additional omega-3 fatty
acid content in the enhanced trout and incorporating that into the total n-3 consumed may have
increased the error. This could be remedied in future studies by collecting the end of study food
diary after participants have finished consuming their two servings of trout per week. One
strength of this study was that participants were motivated and enjoyed consuming the fish.
Another strength is that the participants were consuming fish from a uniform source, which
would reduce any potential differences in n-3 content in the fillets.
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CONCLUSION
In the present study, we were successful in showing that inclusion of two servings of an
omega-3 enhanced fish per week significantly increased omega-3 consumption in a group of
post-menopausal women. Non-significant decreases in CRP and triglycerides were seen in
participants consuming the omega-3 enhanced fish, suggesting the potential for marine derived
omega-3 fatty acids to decrease risk for CVD in post-menopausal women. Future studies on a
larger scale need to be done to confirm the role of omega-3 enhanced fish on markers of heart
disease in post-menopausal women.
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APPENDIX 1: Advertisements

Flier Posted on Campus (2 pages)
Electronic Announcement
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The Human Nutrition and Foods Program at WVU is looking for
postmenopausal women for a research project conducted by Dr. Cindy
Fitch about nutrition and C-reactive protein, a screening test for heart
disease. To qualify, you must be a woman who:
Has gone through natural or surgical menopause.
Is not taking hormone replacement therapy.
Does not have a chronic inflammatory disease.
Has not been diagnosed with any type of heart disease.
Does not currently smoke.
The study will take place in the Morgantown area between April and June
2009. All participants will be asked to follow a heart healthy diet and some
will be asked to eat two servings of fish each week, which will be provided
free of charge. Participants in this study will be asked to:
Attend an informational group meeting.
Complete pre- and post- assessment surveys.
Keep track of your food and drink intake for two 7-day periods.
Keep track of your fish intake during the 8 week study period.
Have blood drawn at a local LabCorp facility at the beginning and
end of the study.
Keep from consuming any omega-3 enhanced food products, fish not
provided by the study or fish oil supplements during the study.
The total time commitment is expected to be about 3 hours at the beginning
and the end of the study.
For more information, call Cindy Fitch at 293-2796 ext. 3341 or email
troutstudy@mail.wvu.edu
Deadline to enroll in study: April 5, 2009

IRB approval on file, please contact
Cindy Fitch to request a copy.
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Facts about Heart Disease

Leading cause of death in the United States and in West Virginia.
Approximately 40% of all deaths are due to heart disease and stroke.
West Virginia has the third highest rate of death from heart disease.
Rates are 2-3 times greater among postmenopausal women.
64% of women who die suddenly have no prior symptoms.
Common risk factors include smoking, high cholesterol, high blood pressure,
physical inactivity, obesity and diabetes
New risk factors include markers of inflammation, such as C-reactive protein,
which can be present when other risk factors are not.
Consuming products that reduce inflammation may decrease risk for heart
disease by reducing levels of C-reactive protein.
Foods that may reduce inflammation include fatty fish, cherries, and fruits and
vegetables. Eating a high fiber diet and participating in regular exercise may also
reduce inflammation.
Fatty fish are high in omega-3 fatty acids, which are known to reduce
inflammation.
Fatty fish include mackerel, trout, herring, sardines, albacore tuna and salmon.
Consumption of fatty fish 1-2 times per week may reduce the risk for heart
disease by decreasing levels of C-reactive protein in your body.

Sources:
American Heart Association
CDC Division for Heart Disease and Stroke Prevention
West Virginia Department of Health & Human Resources
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E-News Announcement
The Human Nutrition and Foods Program at WVU is looking for postmenopausal women for a
research project conducted by Dr. Cindy Fitch about nutrition and C-reactive protein, a screening
test for heart disease. To qualify, you must be a woman
who has gone through natural or surgical menopause,
has not been diagnosed with any type of heart disease, and
does not currently smoke.
Participating women will learn about heart healthy eating and half of them will eat fish each
week for two months. You will be asked to
attend an informational group meeting,
fill out a survey,
keep track of your food and drink intake, and
have blood drawn at a local LabCorp facility at the beginning and end of the two months.
The total time commitment is expected to be about 3 hours at the beginning and the end of the
study (2 months). Fish will be provided free to participants who are assigned to the fish group.
You may or may not be assigned to the “free fish” group. IRB approval for this study is on file.
For more information, call Cindy Fitch at 293-2796 ext 3341. Deadline to apply is April 5, 2009.
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APPENDIX 2: Participant Forms Pre and Post-Study

Fish Group Instructions (2 pages)
No-Fish Group Instructions (2 pages)
Recommendations for a Heart Healthy Diet
Fish Calendar (fish group only)
Food Diary Log (15 pages)
Baseline Survey (3 pages)
Trout Recipes (fish group only, 2 pages)
Safe Handling Instructions
IPAQ (2 pages)
Informed Consent (5 pages)
HIPAA (4 pages)
End of Study Survey (2 pages)
Post-Study Meeting Handout (2 pages)
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Fish Group Instructions
Welcome to the study! You have been selected to be a member of our “fish” group.
Throughout the next few weeks, we will be asking you to have blood work done at a local
LabCorp facility, record everything you eat and drink for two 7 day periods and consume
two servings of fish per week while following recommendations for a heart healthy diet.
Tonight you will be receiving paperwork to have blood taken at LabCorp and your
baseline food diary form. You will receive your fish at the end of next week (week 1) or
the beginning of the following week (week 2) when you hand in your baseline food diary.
You may be wondering, what do I do next? Below is a timeline of what to expect over
the course of the following weeks.
Week
0
1

2
3
4
5
6
7
8
9
10
11

Action
Attend Pre-Study Meeting
Record Food Intake
Blood work at LabCorp
Hand in food log
Pick up fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Eat 2 Servings of fish
Record Food Intake
Blood work at LabCorp
Attend Post-Study Meeting
Hand in food log

Food logs can be returned when you come to pick up your fish, mailing to the address
provided or arranging a time to drop them off.
If you have any questions about the study, please contact Dr. Cindy Fitch at
304.293.2796 x 3341 or email troutstudy@mail.wvu.edu
Thank you for your participation!
Visit the study’s website at: http://www.caf.wvu.edu/afmdp/FishandYourHeart.html
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Things to Do
1.
2.
3.
4.
5.
6.

Eat a heart healthy diet.
Consume 2 servings of study provided fish per week.
Record everything you eat and drink during week 1 and week 9.
Use the provided calendar to record when you eat the study fish.
Have blood drawn at LabCorp during week 1 and week 10.
Contact us if you start taking any medications or are diagnosed with an illness at
any time throughout the study.

Things to Avoid*
1.
2.
3.
4.
5.
6.

Do not eat any fish other than what is provided for the study.
Do not consume and omega-3, DHA or EPA enhanced products.
Do not consume flax seed or flax seed oil.
Do not take fish oil supplements.
Do not take anti-inflammatory medications on a daily basis.
Do not start hormone replacement therapy.

*Please always follow the advice of your medical doctor. If your doctor
prescribes medication that conflicts with study requirements, please contact
us to stop participation in the study.*
Local LabCorp Facilities:
Internal Medicine Associates, Inc.
99 J.D. Anderson Drive
Morgantown, WV 26505
304-598-9761
Medical Arts Laboratory
200 Wedgewood Drive
Morgantown, WV 26505
304-599-8324
Lab Corp.
501 Locust Ave.
Fairmont, WV 26554
800-352-3141
Please visit https://www.newlabcorp.com/wps/portal/findalab to locate additional
facilities in your area.
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No-Fish Group Instructions
Welcome to the study! You have been selected to be a member of our “no fish” group.
Throughout the next few weeks, we will be asking you to have blood work done at a local
LabCorp facility, record everything you eat and drink for two 7 day periods and follow
recommendations for a heart healthy diet. In addition, we would like for you to refrain
from consuming any of the following during the study: fish, fish oils, omega-3 enhanced
food and anti-inflammatory medications.
You may be wondering, what do I do next? Below is a timeline of what to expect over
the course of the following weeks.

Week
0
1

2
3
4
5
6
7
8
9
10
11

Action
Attend Pre-Study Meeting
Record Food Intake
Blood work at LabCorp
Hand in food log
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Eat Heart Healthy Diet
Record Food Intake
Blood work at LabCorp
Attend Post-Study Meeting
Hand in food log

Food logs can be returned by mailing to the address provided or emailing
troutstudy@mail.wvu.edu to arrange a time to drop them off.
If you have any questions about the study, please contact Dr. Cindy Fitch at
304.293.2796 x 3341 or email troutstudy@mail.wvu.edu
Thank you for your participation!
Visit the study’s website at: http://www.caf.wvu.edu/afmdp/FishandYourHeart.html
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Things to Do
7. Eat a heart healthy diet.
8. Record everything you eat and drink during week 1 and week 9.
9. Have blood drawn at LabCorp during week 1 and week 10.
10. Contact us if you start taking any medications at any time throughout the study.

Things to Avoid*
7. Do not eat any fish for the duration of the study.
8. Do not consume and omega-3, DHA or EPA enhanced products.
9. Do not consume flax seed or flax seed oil.
10. Do not take fish oil supplements.
11. Do not take anti-inflammatory medications on a daily basis.
12. Do not start hormone replacement therapy.

*Please always follow the advice of your medical doctor. If your doctor
prescribes medication that conflicts with study requirements, please contact
us to stop participation in the study.*
Local LabCorp Facilities:
Internal Medicine Associates, Inc.
99 J.D. Anderson Drive
Morgantown, WV 26505
304-598-9761
Medical Arts Laboratory
200 Wedgewood Drive
Morgantown, WV 26505
304-599-8324
Lab Corp.
501 Locust Ave.
Fairmont, WV 26554
800-352-3141
Please visit https://www.newlabcorp.com/wps/portal/findalab to locate additional
facilities in your area.
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Recommendations for a Heart Healthy Diet
The American Heart Association recommends reducing overall fat intake to 2535% of your daily calories with saturated fat less than 7% and trans fat less than
1% of your daily calories. In addition, they recommend a varied diet that includes
fruits, vegetables and whole grains, is high in fiber (25-30 grams/day) and low in
sodium (less than 2300 mg/day or less than 1500mg/day for those with high
blood pressure). Below is a list of food items to include in a heart healthy diet.
Skim or low-fat milk (1%)
Fat free or low fat dairy products such as cheese and yogurt
Egg whites or egg substitutes
Fish, especially fatty (no fish during the study!)
Skinless poultry
Legumes
Soybeans and soy products
Lean ground meats
Fresh or frozen fruits and vegetables
Low-sodium or rinsed canned vegetables
Canned fruit packed in juice or water
Whole wheat flour
Whole grain bread, preferably 100% whole wheat or 100% whole grain
High fiber cereal with 5 or more grams of fiber per serving
Brown rice
Whole-grain pasta
Oatmeal (steel-cut or regular)
Ground flaxseed (no flaxseed or flaxseed oil during the study!)
Herbs and spices
Reduced-salt canned soups or prepared meals
Olive oil
Canola oil
Margarine labeled trans-fat free
*For more heart healthy recommendations visit the American Heart Association,
American Dietetic Association and the Mayo Clinic on the web
*For
recipe
ideas
visit:
deliciousdecisions.org,
eatingwell.com, and cookinglight.com

goredforwomen.org,
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Week
2

Sunday

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

3
4
5
6
7
8
9

Please indicate the day and meal (breakfast, lunch, dinner, or snack) you ate the study fish. Sample:
Week 5

Dinner

snack
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Fish and Your Heart
Daily Food Record
Pre-Study Log
Instructions: For seven days, starting this Sunday through the following
Saturday, we would like you to keep a record of your dietary intake. Use the
attached charts to keep track of the foods you eat on the selected days. Follow
the instructions that have been provided in order to complete the most accurate
daily food record possible.
Record everything you eat and drink for 7 days. Include the date and day of
the week at the top of each form. Start with the first thing you consume this
Sunday and end with the last thing you consume the following Saturday. Each
line of the food diary is for one food item, not an entire meal!
Use a separate form for each day. Use more than one form if needed for one
day, but begin a new form for each new day.
Keep it with you. Carry the food record with you during the day. It is
surprisingly difficult to recall what you ate hours or days later.
Include details. Record anything added to the food such as sugar, ketchup,
margarine or salad dressing.
Describe combination foods. If you are eating a combination food such as
pizza with various toppings, make sure to record all ingredients. Record brand
names for packaged foods and restaurant names for foods eaten out.
Save labels. When you can, please save the nutrient labels from the packaged
foods you eat and bring them with you when you turn in your food log.
Estimate serving size. To the best of your ability, estimate the serving size.
Use the serving size on the food label if available. Use measuring cups and
spoons at home. If you are uncertain, estimate using familiar objects. For
example, you can use “palm of my hand” to estimate the size of a chicken
breast or “baseball” to estimate a serving of ice cream.
Record time. Record the approximate time each meal or snack is eaten.
Write down beverages. Record all beverages that you consume. This
includes no-calorie drinks such as diet sodas, unsweetened tea and water.
Write down any vitamin or other supplements that you take. Include the
brand name and amount you took.
Bring the record and food labels with you when you pick up your fish!
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Fish and Your Heart
Daily Food Record
Day 1 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Fish and Your Heart
Daily Food Record
Day 2 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Fish and Your Heart
Daily Food Record
Day 3 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Fish and Your Heart
Daily Food Record
Day 4 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Fish and Your Heart
Daily Food Record
Day 5 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Fish and Your Heart
Daily Food Record
Day 6 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Fish and Your Heart
Daily Food Record
Day 7 – Pre-Study
Name: _________________________________
Day of the Week:
Time

SUN

MON

TUES

WED

Date: ________________
THUR

FRI

SAT

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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Time

Food/Drink

Method of Preparation

Amount

Type of food, brand name,
restaurant

Description, product
label or recipe

Tsp, tbsp,
cup, oz,
weight or
portion
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FISH and HEART DISEASE STUDY
Baseline Survey
Today’s Date:

Name:

ID#:

We’d like to get some information about you and your health habits to help us understand the
results of this study. Please complete the following items by clearly writing or circling your
answer.
Demographics
1. How old were you on your last birthday? _________ years
2. Circle your marital status.
a- Single
b- Married
c- Divorced
d- Widowed
3. Circle the highest education level you finished.
a- Grade school or less
b- High school or GED
c- Some college
d- College
e- Graduate degree
4. Circle which best describes your race.
a- White (nonHispanic)
b- African American (nonHispanic)
c- Hispanic
d- Asian
e- Native American
Health Conditions
5. Circle the method of menopause you experienced.
a- natural
b- surgical (complete hysterectomy)
c- other: please describe _____________________
6. What was the month and year of your last period? _________(month) ________ (year)
7. Did either of your parents have a heart attack before they were 60 years old? Yes / No
8. What is your height? _______ (feet) ___________ (inches)
9. What is your weight? ____________ (pounds)

3/8/2010
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10. Please list any heart-related conditions you have. Write ‘none’ if you do not have any.
___________________________________________________________________________
___________________________________________________________________________
11. Please list all medications you are currently taking. Write ‘none’ if you are not taking any.
___________________________________________________________________________
___________________________________________________________________________

Lifestyle habits
12. Circle your smoking status.
a- I smoke occasionally
b- I used to smoke but quit
c- I never smoked
13. Circle how often you usually exercise (sweat and breath heavy for 20 minutes or more).
a- A few times a week
b- Once a week
c- Less than once a week
14. Circle how often you usually have an alcoholic beverage (beer, wine, or hard liquor).
a- Every day
b- A few times a week
c- A few times a month
d- A few times a year
e- I never drink alcohol
15. Circle how often you usually take aspirin. This DOES NOT include Tylenol or ibuprofen.
a- Every day
b- A few times a week
c- A few times a month
d- A few times a year
e- I never use aspirin
16. Circle how often you usually take ibuprofen (trade name Motrin or Rufen).
a- Every day
a- A few times a week
b- A few times a month
c- A few times a year
d- I never use ibuprofen
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17. Please circle all of the following anti-inflammatory medications that you are currently taking
or have taken in the past year.
Glucocorticoids
Hydrocortisone

Betamethasone

Cortisone

Dexamethasone

Prednisone

Paramethasone

Prednisolone

Triamcinolone

Methylprednisolone
Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Generic Name
Magnesium salicylate

Trade Name
Mobidin, Magan

Choline salicylate

Arthropan liquid

Choline magnesium trisalicylate

Trilisate

Salsalate

Disalcid

Diclofenac sodium

Voltaren

Diflunisal

Dolobid

Fenoprofen calcium

Nalfon

Flurbiprofen

Ansaid

Indomethacin

Indocin

Ketoprofen

Orudis

Meclofenamate sodium

Meclomen

Naproxen

Naprosyn

Naproxen sodium

Anaprox

Phenylbutazone

Butazolidin

Piroxicam

Feldene

Sulindac

Clinoril

Tolmetin sodium

Tolectin

Thank you for participating in this study.
We look forward to working with you.
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More Quick Meal Ideas

TROUT RECIPES
__________________________________________________

Cook fillet in microwave. Flake and add to canned vegetable
soup or potato-corn chowder.
Cook fillet in microwave. Flake and toss with pasta,
vegetables and Italian dressing.
Pan-fry fillet and add to tossed green salad. Serve with
crusty bread.
Pan-fry fillet and serve on a warmed bun with lettuce and
tomato.

More Seasoning Suggestions
Cook fish plain using any method, then serve with your
choice of sauce.
o
o
o

Barbeque
Cheese
Marinara

o Teriyaki
o Salsa
o Mushroom

Brush fillet with oil, sprinkle on one of the following
seasonings, then broil.
o
o
o

Lemon Pepper
Old Bay Seasoning
Italian Seasoning Mix

PREPARATION POINTERS
Baking
Trout is best baked at a moderately high temperature, 400450°F, for a short period of time. Enhance moistness and
flavor with seasoned oil. Test for doneness by probing with a
fork. If the fish flakes easily, it is done. Do not try to turn the
fish during the baking process.
Broiling
Place the trout no closer than 4 inches to the source of heat.
Baste well with an oil or sauce before and during the cooking
process to prevent the fish from being too dry.
Grilling
Place the trout fillet on foil and grill approximately 4-6 inches
from the hot charcoal. Cooking time varies with the
temperature of the grill. It will require about 3-4 minutes.
Pan-Frying
Use a small amount of oil. Roll the fish in a coating and fry
lightly or sauté at a moderate temperature until browned on
one side. Trout is done when the flesh flakes easily with a fork.
Microwave
Microwave cooking is especially suited to the high temperature
and short time required for cooking trout. Always thaw trout
completely to ensure an even cooking. Cover the fish with
plastic wrap, but turn back one corner to allow venting. Cook
fillet at HIGH for ~1 minute (less for plain fish, more for fish
with sauce). Allow the fish to stand 1 minute to complete
cooking.
Tip: Overcooking trout dries out and toughens the fish. Trout is
done when it flakes easily with a fork.

DO NOT DEEP-FAT FRY THE STUDY FISH
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Baked Parmesan Trout
1 Tbsp grated Parmesan cheese

2 Tbsp toasted breadcrumbs
1 dash pepper
1 dash paprika

1 Tbsp skim milk
1 dash hot pepper sauce
1 trout fillet

Preheat oven to 400°F. Combine Parmesan cheese, bread
crumbs, pepper and paprika. In another bowl, combine milk
and hot sauce. Dip fillet in milk mixture. Coat with breadcrumb
mixture. Place fish on baking dish. Bake 10 minutes or until
golden brown.
Cajun Baked Trout
1 Tbsp Cajun seasoning
1 Tbsp water
1 trout fillet
Preheat oven to 400 degrees. Mix the water and seasoning
together; brush onto the trout fillet and bake on a pan sprayed
with nonstick spray. Bake about 10 minutes or until done. More
seasoning can be added if you like a spicier taste.
Lemon Broiled Trout
1 trout fillet
1 dash paprika
1 Tbsp lemon juice
1 tsp oil
1 dash salt
Brush fish with oil and place on baking pan. Sprinkle with salt
and paprika. Broil 4 inches from the heat for 2 minutes.
Remove and pour lemon juice over fish. Broil another 2
minutes.

Basic Pan-Fried Trout
1 trout fillet
1 Tbsp flour
1 Tbsp milk
oil for pan-fry
Dip fillet in milk then dredge in flour. Pan-fry in small amount of
oil. Serve with lemon wedges or your choice of sauce.
Breaded Pan-Fried Trout
1 trout fillet
oil for pan-fry
1 Tbsp milk
½ cup marinara sauce (optional)
2 Tbsp seasoned breadcrumbs
Dip fillet in milk. Coat with breadcrumbs. Pan-fry in oil. Serve
with marinara sauce.
Microwave Teriyaki Trout
2 tsp soy sauce
½ small clove garlic, minced
¼ tsp sugar
1 trout fillet
¼ tsp ground ginger
In small bowl, combine soy sauce, sugar, ginger and garlic.
Place fish in microwave-safe dish. Pour sauce over fish. Cover
and microwave 2 minutes on high or until trout flakes easily.
Trout Salad Sandwich
1 trout fillet
1 Tbsp lite mayonnaise

½ stalk celery, chopped
2 slices bread or pita pocket

Place fillet in microwave-safe dish. Cover loosely. Cook on
HIGH ~45 seconds or until done. Cool. Flake fish and mix with
mayonnaise and celery. Serve on bread with your choice of
fixings.

Zippy Broiled Trout
1 trout fillet
1 Tbsp bottled Italian salad dressing
Dip fish in dressing and place on baking pan. Broil 4 inches
from heat for 4 minutes.
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WVU FISH STUDY
Contents: 16 uncooked fillets rainbow trout.
For consumption by study participants only.

KEEP FISH FROZEN UNTIL READY TO USE.
See reverse side for handling instructions.

The Fish Study is being conducted by
WVU College of Agriculture
Division of Animal and Nutritional Sciences
Direct questions regarding the fish to Cindy Fitch 304-293-2631 ext 4415

SAFE FISH HANDLING INSTRUCTIONS
THAWING
Never defrost on counter top or in warm water. Use one of the following methods.
Do not refreeze uncooked fish.
Refrigerator Place unopened fillet bag in refrigerator and let thaw overnight.
Cold water Place unopened fillet bag in pan of cold water and change water every 30
minutes. Or thaw in unopened bag under cold running water.
Microwave Cut bag open and place bag of fish in microwave-safe dish. Thaw on defrost
setting for 2-3 minutes. Fish must be cooked immediately following microwave defrosting.
PREPARATION
Always wash hands thoroughly with hot, soapy water before preparing foods and after handling raw
fish. Don’t let raw fish or juices touch ready-to-go foods either in the refrigerator or during preparation.
Don’t put cooked foods on the same plate that held raw fish. Always wash utensils that have touched
raw fish with hot, soapy water before using them for cooked foods. Wash counters, cutting boards
and other surfaces raw fish have touched.
COOKING
Cook the fish until it begins to flake and loses its translucent or raw appearance.
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE
We are interested in finding out about the kinds of physical activities that people do as
part of their everyday lives. The questions will ask you about the time you spent being
physically active in the last 7 days. Please answer each question even if you do not
consider yourself to be an active person. Please think about the activities you do at
work, as part of your house and yard work, to get from place to place, and in your spare
time for recreation, exercise or sport.
Think about all the vigorous activities that you did in the last 7 days. Vigorous
physical activities refer to activities that take hard physical effort and make you breathe
much harder than normal. Think only about those physical activities that you did for at
least 10 minutes at a time.
1.

During the last 7 days, on how many days did you do vigorous physical
activities like heavy lifting, digging, aerobics, or fast bicycling?
_____ days per week
No vigorous physical activities

2.

Skip to question 3

How much time did you usually spend doing vigorous physical activities on one
of those days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

Think about all the moderate activities that you did in the last 7 days. Moderate
activities refer to activities that take moderate physical effort and make you breathe
somewhat harder than normal. Think only about those physical activities that you did
for at least 10 minutes at a time.

3.

During the last 7 days, on how many days did you do moderate physical
activities like carrying light loads, bicycling at a regular pace, or doubles tennis?
Do not include walking.
_____ days per week
No moderate physical activities

Skip to question 5

SHORT LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ. Revised August 2002.
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4.

How much time did you usually spend doing moderate physical activities on one
of those days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

Think about the time you spent walking in the last 7 days. This includes at work and at
home, walking to travel from place to place, and any other walking that you might do
solely for recreation, sport, exercise, or leisure.
5.

During the last 7 days, on how many days did you walk for at least 10 minutes
at a time?
_____ days per week
No walking

6.

Skip to question 7

How much time did you usually spend walking on one of those days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

The last question is about the time you spent sitting on weekdays during the last 7
days. Include time spent at work, at home, while doing course work and during leisure
time. This may include time spent sitting at a desk, visiting friends, reading, or sitting or
lying down to watch television.
7. During the last 7 days, how much time did you spend sitting on a week day?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

This is the end of the questionnaire, thank you for participating.

SHORT LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ. Revised August 2002.
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CONSENT AND INFORMATION FORM
OMR ICF
Principal Investigator: Fitch, Cindy
Department:
AGRICULTURE & FORESTRY - Animal/Vet. Science
Tracking Number:
H-20810
Study Title:
The Effects of Omega-3 Enriched Trout on C-Reactive Protein
Concentrations
Co-Investigator(s):
Fitch, Cindy, Moran, Megan
Sponsor
US Department of Agriculture
Contact Persons
If you have any questions, concerns, or complaints about this research,
you can contact Dr. Cindy Fitch at 304/293-2631, extension 4415
For information regarding your rights as a research subject, you may contact the Office of
Research Compliance at 304/293-7073.
Introduction
You, _____________________, have been asked to participate in this
research study, which has been explained to you by
_____________________________. This study is being conducted
by Cindy Fitch, Ph.D., RD in the Department of Human Nutrition and
Foods at West Virginia University with funding provided by the US
Department of Agriculture.
Purposes of the Study
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The purpose of this study is to learn more about diet and heart health.
WVU expects to enroll approximately 60 subjects; a total of
approximately 60 subjects at all sites are expected to participate in this
study.
Description of Procedures
This study involves attending an informational meeting at the beginning
and end of the study and will take approximately 1 hour. You will be asked
to fill out a questionnaire regarding your health history. This will take
approximately 30 minutes. You do not have to answer all the questions.
You will have the opportunity to see the questionnaire before signing this
consent form. You will also be asked to keep track of everything that you
eat or drink for 7 days at the beginning and end of the study and to
participate in 2 phone calls with a registered dietitian. Each phone call will
last about 30 minutes and you will be asked questions about the food you
ate. You do not need to answer any question that make you feel
uncomfortable. You will be asked to go to a local Lab Corp clinic to have
blood drawn at the beginning and end of the study. You will be provided
with directions to the nearest Lab Corp facility and their business hours.
You may go anytime within the first week of the study that is convenient to
you. You will need to arrange your own transportation. About 1 tablespoon
will be drawn from a vein in your arm each time for a total of 2 tablespoons
during the study. The total amount of blood withdrawn during the study
will be about one—fifteenth (1/15) of what is taken for a standard blood
donation. There will be no cost to you for the blood draw. The following
laboratory values will be measured in the blood; C—reactive protein,
interleukin 6, total, LDL— and HDL—cholesterol, and triglycerides. You will
be randomly assigned (like flipping a coin) to a study group. If you are
assigned to the control group, you will eat your usual diet for the 8—week
study. If you are assigned to the fish group, you will be asked to eat
omega—3—enriched fish twice a week for 8 weeks. The fish will be
provided free and you will need to pick them up at the designated time and
place.
Risks and Discomforts
Having blood drawn may cause bruising, bleeding, or in rare cases,
infection. The fish will be grown and processed in West Virginia University
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Tracking
#:
infection.

H-20810
The
fish will be grown and processed in West Virginia University
facilities where they will be monitored and tested for safety. There are no
expected risks or side effects from eating the fish.

Alternatives
You do not have to participate in this study.
Alternatives that could be considered in your case include not participating
in the study.
Benefits
You may not receive any direct benefit from this study. The knowledge
gained from this study may eventually benefit others.
Financial Considerations
There are no special fees for participating in this study. The fish will be
provided free to those who are randomly assigned to the fish group. The
cost of the lab tests will be paid by the study and neither you nor your
insurance company will be charged.
Confidentiality
Any information about you that is obtained as a result of your participation
in this research will be kept as confidential as legally possible. Your
research records and test results, just like hospital records, may be
subpoenaed by court order or may be inspected by federal regulatory
authorities without your additional consent. A special number will be used
to identify you in the study and only the investigators will know your name.
In any publications that result from this research, neither your name nor
any information from which you might be identified will be published
without your consent.
Voluntary Participation
Participation in this study is voluntary. You are free to withdraw your
consent to participate in this study at any time. Refusal to participate or
withdrawal will not affect your future care and will involve no penalty to
you. In the event new information becomes available that may affect your
willingness to participate in this study, this information will be given to you
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so that you can make an informed decision about whether or not to
continue your participation. You have been given the opportunity to ask
questions about the research, and you have received answers concerning
areas you did not understand.
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Upon signing this form, you will receive a copy.
I willingly consent to participate in this research.

Signature of Subject or
Subjects Legal Representative

Printed Name

Date

Time

The participant has had the opportunity to have questions addressed. The participant willingly
agrees to be in the study.

Signature of Investigator or
Co-Investigator
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Effects of Omega-3 Enriched Fish Consumption on C-Reactive Protein in PostMenopausal Women
Principal Investigator: Fitch, Cindy
Department:
AGRICULTURE & FORESTRY - Animal/Vet. Science
Tracking Number:
H-20810
Study Title:
The Effects of Omega-3 Enriched Trout on C-Reactive Protein
Concentrations
Co-Investigator(s):
Fitch, Cindy, Moran, Megan
Sponsor
West Virginia University Aquaculture Research and Marketing Project
Subject´s Name: _________________________ ID
Number:_____________
We know that information about you and your health is private. We are
dedicated to protecting the privacy of that information. Because of this
promise, we must get your written authorization (permission) before we
may use or disclose your protected health information or share it with
others for research purposes. This form gives that permission. It also helps
us make sure that you are correctly told how this information will be used
or disclosed. Please read the information below carefully before signing this
form. Please ask any questions you may have about this form or its uses.
You can decide to sign or not to sign this authorization form. However, if
you choose not to sign this authorization form, you will not be able to take
part in the research study. Whatever choice you make about this research
study, it will not have an effect on your access to medical care.
USE AND DISCLOSURE COVERED BY THIS AUTHORIZATION
DO NOT SIGN A BLANK FORM. You or your authorized representative
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should thoroughly read the information below before signing this form.
Who will disclose, receive, and/or use the information? This form will
authorize the following person(s), class(es) of persons, and/or organization
(s) to disclose, use, and receive the information*:
Study investigators, clinical coordinator, laboratory personnel;
The research site(s) carrying out this study (WVU and LabCorp). It also
includes each site´s research staff and medical staff.
Health care providers who provide services to you as part of this research
study.
Laboratories and other people and groups that look into your health
information as part of this study in agreement with the study protocol.
The United States Department of Health and Human Services (which
includes the National Institutes of Health, Food and Drug Administration
(FDA) and other groups that have the right to use the information as
required by law.
* If, during the course of the research, one of the companies or institutions
listed above merges with, or is purchased by, another company or
institution, this authorization to use or disclose protected health
information in the research will extend to the successorcompany or
institution.
What information will be used or disclosed?
Information that will be used for the purposes of the study include answers
to survey questions, dietary intake data, and results of laboratory tests,
(C—reactive protein, interleukin 6, total, LDL— and HDL—cholesterol, and
triglycerides).
SPECIFIC UNDERSTANDINGS
By signing this research authorization form, you give permission for the
use and/or disclosure of your protected health information described
above. The purpose for the uses and disclosures you are authorizing is to
carry out the research study explained to you during the informed consent
process. It is also to ensure that the information relating to the research is
available to all parties who may need it for research purposes. Your
protected health information may be used as necessary for your researchrelated treatment or to collect payment for your research-related treatment
(when applicable). It may also be used to run the business operations of
the institution.
This information may be redisclosed or used for other purposes if a
Tracking #:

H-20810

Approved On:

05/07/2008

Valid Through:

05/06/2009

Last Amended:

N/A

Page

2 of 4
Initials

Date

76

Tracking #:
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recipient described in this form is not required by law to protect the privacy
of the information.
You have a right to refuse to sign this authorization. Your health care
outside the study, the payment for your health care, and your health care
benefits will NOT be affected if you do not sign this form. However you will
NOT be able to take part in the research study described in this
authorization if you do not sign this form.
If you sign this authorization, you will have the right to cancel it at any
time, except to the extent that WVU Division of Animal and Nutritional
Sciences has already taken action based upon your authorization or needs
the information to complete analysis and reports of data for this research
study. To cancel this authorization, please write to the Principal
Investigator, Cindy Fitch, Ph.D., RD at: Mailbox #:6108, Morgantown, WV
26506-6108.
You will be allowed to see or copy the information described on this form
as long as the research is in progress, but you have a right to see and copy
the information upon completion of the research in accordance with
hospital policies.
The members and staff of any Institutional Review Board (IRB) that
oversees this research study.
The Principal Investigator: Dr. Cindy Fitch
Members of WVU, Division of Animal and Nutritional
Sciences administrative staff responsible for administering clinical trials and
other research activities, including the Clinical Trials, Office/Office of
Research and Sponsored Programs.
You have a right to receive a copy of this form after you have signed it.
Expiration Date: ________________
THE SUBJECT OR HIS/HER AUTHORIZED REPRESENTATIVE MUST BE
PROVIDED WITH A COPY OF THIS FORM AFTER IT HAS BEEN SIGNED.
SIGNATURE
I have read this form and all of my questions about this form have been
answered. By signing below, I acknowledge that I have read and accept all
of the above.
___________________________________________
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H-20810
Tracking
#:
___________________________________________

__________________________
Signature of Subject or Authorized Representative Date
_________________________________________________
Print Name of Subject or Authorized Representative
_________________________________________________
Relationship of the person signing as Subject or Authorized Representative
above to the Subject
_________________________________________________
Print Name of Individual Explaining this Research Authorization Form
CONTACT INFORMATION
The contact information of the subject or authorized representative who
signed this form should be filled in below.
Address:
____________________________
____________________________
____________________________
____________________________
Telephone:
___________________ (daytime)
___________________ (evening)
____________________________
E-mail Address (optional):
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FISH and HEART DISEASE STUDY
Post Survey
Today’s Date:

Name:

ID#:

Changes during the Study
We want to know if certain things changed for you during the study.
Please circle whether or not the following happened DURING THE 12-WEEK STUDY.
1. I was diagnosed with diabetes.

Yes

No

2. I was diagnosed with high blood pressure (hypertension).

Yes

No

3. I was diagnosed with heart disease (such as angina, congestive heart

Yes

No

4. I had a heart attack.

Yes

No

5. I had a major injury (such as a broken bone or severe burn).

Yes

No

6. I had surgery.

Yes

No

7. I gained more than 5 pounds.

Yes

No

8. I lost more than 5 pounds.

Yes

No

failure, peripheral arterial disease).
If yes, please describe:

If yes, please describe:

9. Please mark (X) which changes you made to follow a heart healthy diet for this study.
______ Reduced amount of commercial salad dressing I used.
______ Reduced amount of margarine I used.
______ Reduced amount of mayonnaise I used.
______ Reduced amount of full-fat dairy products I ate.

Version 3/8/2010
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Satisfaction with the Study Experience
We want to know your thoughts about eating the fish and being a part of the study.
On a scale of 1-5 please rate the following items.

10. I liked the taste of the fish provided by the study.

Strongly
Agree
1
2

3

Strongly
Disagree
4
5

11. It was convenient getting the fish for the study.

1

2

3

4

5

12. It was easy to prepare the fish for meals.

1

2

3

4

5

13. It was hard trying to eat the fish twice a week.

1

2

3

4

5

14. I may try to keep eating fish twice a week.

1

2

3

4

5

15. I learned new ways to eat heart healthy.

1

2

3

4

5

16. The heart healthy diet had too many changes.

1

2

3

4

5

17. I want to keep eating a heart healthy diet.

1

2

3

4

5

18. How could we make it easier to eat the fish twice a week in future studies?

19. What did you like the least about being in the study?

20. What did you like the most about being in the study?

Thank you for being part of this study.
Your contribution may help the health of other women.

Version 3/8/2010
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Thanks for participating in the study!
Tonight you will be receiving your blood work results and nutrition analysis. If you have
questions or concerns about any of the results, please contact your physician.
To help you understand where your diet may need changes, the following
recommendations were published in the 2005 Dietary Guidelines for Americans:
- Carbohydrates should be between 45 and 65% of the total calories consumed
- Total fats should be between 20 and 35% of the total calories consumed
- Saturated fats should be limited to less than 10% of your total calories
- Protein should be between 10 and 35% of total calories consumed
- Sodium intake should be less than 2300 mg per day
- Fiber intake should be approximately 14 grams per every 1,000 calories
The following table shows calorie guidelines from the American Heart Association:
Activity Level and Estimated Calories Burned
1

2

Active

3

Gender

Age
(years)

Sedentary

Moderately Active

Female

19–30

2,000

2,000-2,200

2,400

31–50

1,800

2,000

2,200

51+

1,600

1,800

2,000-2,200

Ranges for CRP levels are as follows:
Low - less than 1
Average - 1 to 3
High - greater than 3

The following tables are from the American Heart Association and give the ranges
for cholesterol and triglycerides.
Total Cholesterol Level

Category

Less than 200 mg/dL

Desirable level that puts you at lower risk
for coronary heart disease. A cholesterol
level of 200 mg/dL or higher raises your
risk.

200 to 239 mg/dL

Borderline high

240 mg/dL and above

High blood cholesterol. A person with this
level has more than twice the risk of
coronary heart disease as someone whose
cholesterol is below 200 mg/dL.
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HDL Cholesterol Level

Category

Less than 40 mg/dL
(for men)
Less than 50 mg/dL
(for women)

Low HDL cholesterol. A major risk factor
for heart disease.

60 mg/dL and above

High HDL cholesterol. An HDL of 60
mg/dL and above is considered protective
against heart disease.

LDL Cholesterol Level

Category

Less than 100 mg/dL

Optimal

100 to 129 mg/dL

Near or above optimal

130 to 159 mg/dL

Borderline high

160 to 189 mg/dL

High

190 mg/dL and above

Very high

Triglyceride Level

Category

Less than 150 mg/dL

Normal

150–199 mg/dL

Borderline high

200–499 mg/dL

High

500 mg/dL and above

Very high

For more information, visit:
http://www.americanheart.org
http://www.eatright.org
http://www.americanheart.org/presenter.jhtml?identifier=4500
http://www.health.gov/DietaryGuidelines/dga2005/document/default.htm
http://www.americanheart.org/presenter.jhtml?identifier=3055399
http://www.americanheart.org/presenter.jhtml?identifier=3055398

John H.
Hagen
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